AXLA Stock Price, Axcella Health Inc Quote, Chart

Market Summary

USD0.40

Market Closed

AXLA Stock Price

View Fullscreen

AXLA RSI Chart

AXLA Valuation

Market Cap

1.2M

Price/Earnings (Trailing)

-0.02

Price/Sales (Trailing)

2.34

Price/Free Cashflow

-0.03

AXLA Price/Sales (Trailing)

AXLA Profitability

Return on Equity

-6.6K%

Return on Assets

-519.61%

Free Cashflow Yield

-3.4K%

AXLA Fundamentals

AXLA Revenue

Revenue (TTM)

504.0K

AXLA Earnings

Earnings (TTM)

-48.2M

Breaking Down AXLA Revenue

Last 7 days

-20%

Last 30 days

-87.5%

Last 90 days

-96.2%

Trailing 12 Months

-94.9%

How does AXLA drawdown profile look like?

AXLA Financial Health

Current Ratio

0.8

AXLA Investor Care

Shares Dilution (1Y)

39.99%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q4
2023	0	0	0
2022	260.7K	382.3K	504.0K
2021	250.3K	194.7K	139.0K
2020	1.3M	808.7K	306.0K
2019	1.2M	0	1.8M
2018	0	0	547.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Axcella Health Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 01, 2023	koziel margaret	sold	-393	0.58	-679	chief medical officer
Feb 10, 2023	fehlner paul	acquired	3,446	0.6602	5,221	svp & chief legal officer
Oct 19, 2022	hinshaw william	sold	-25,027	1.5642	-16,000	president & ceo
Oct 17, 2022	hinshaw william	acquired	-	-	50,000	president & ceo
Oct 13, 2022	societe des produits nestle s.a.	bought	6,000,010	1.64	3,658,540	-
Oct 13, 2022	flagship ventures fund iv general partner llc	bought	5,000,000	1.64	3,048,780	-
Oct 13, 2022	flagship ventures fund iv general partner llc	bought	9,022,020	1.64	5,501,230	-
Oct 13, 2022	flagship ventures fund iv general partner llc	bought	3,007,340	1.64	1,833,740	-
Sep 06, 2022	koziel margaret	sold	-1,378	2.5195	-547	chief medical officer
Jun 01, 2022	koziel margaret	sold	-1,186	2.0107	-590	chief medical officer

Which funds bought or sold AXLA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Lindbrook Capital, LLC	unchanged	-	-32.00	-	-%
Jul 15, 2022	Pinnacle Private Wealth, LLC	added	108	49,000	125,000	0.05%
Jul 28, 2021	Hoover Financial Advisors, Inc.	sold off	-100	-3,000	-	-%

Are Funds Buying or Selling AXLA?

Are funds buying AXLA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AXLA

No. of Funds

Unveiling Axcella Health Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Sep 11, 2023	fmr llc	-	0	SC 13G/A
Feb 14, 2023	harbourvest partners l.p.	8.4%	6,207,929	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 02, 2023	societe des produits nestle s.a.	15.09%	11,105,438	SC 13G/A
Oct 17, 2022	flagship venturelabs iv, llc	2.8%	2,035,830	SC 13D/A
Sep 23, 2022	flagship venturelabs iv, llc	3.9%	2,035,830	SC 13D/A
Mar 29, 2022	harbourvest partners l.p.	8.46%	4,378,661	SC 13G/A
Mar 18, 2022	flagship venturelabs iv, llc	3.9%	2,035,830	SC 13D/A
Feb 09, 2022	fmr llc	-	0	SC 13G/A
Feb 16, 2021	harbourvest partners l.p.	7.5%	2,807,981	SC 13G/A

Recent SEC filings of Axcella Health Inc

View All Filings

Date Filed	Form Type	Document
Feb 15, 2024	25-NSE	25-NSE

Peers (Alternatives to Axcella Health Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Axcella Health Inc News

Latest updates

Axcella Health Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)														(In Thousands)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q2	2022Q1	2021Q4	2021Q2	2021Q1	2020Q4	2020Q2	2020Q1	2019Q4	2019Q1	2018Q4
Revenue	-5.7%	132	140	103	65.00	22.00	35.00	48.00	35.00	27.00	18.00	257	324	390	-
Operating Expenses	-15.3%	3,543	4,183	20,946	20,619	18,330	17,203	15,244	14,496	14,467	13,184	14,460	15,340	11,031	9,163
S&GA Expenses	-15.7%	2,319	2,750	3,500	3,753	4,786	4,736	4,946	4,256	3,869	4,619	4,125	2,745	3,468	1,286
R&D Expenses	-14.6%	1,224	1,433	13,257	16,866	13,544	12,467	10,298	10,240	10,598	8,565	10,335	12,595	7,563	7,877
Interest Expenses	-	-	-	1,146	627	573	1,190	571	566	1,875	-708	669	3,326	881	4,405
Net Income	14.2%	-3,413	-3,976	-23,000	-21,306	-19,039	-17,891	-15,935	-15,189	-15,189	-13,892	-15,009	-15,713	-11,573	-9,762
Net Income Margin	27.1%	-95.69*	-131.20*	-161.08*	-193.15*	-262.70*	-464.95*	-301.80*	-226.53*	-184.73*	-76.57*	-	-	-	-
Free Cashflow	-72.5%	-8,800	-5,100	-15,569	-35,538	-17,026	-13,637	-14,468	-14,195	-10,243	-12,577	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																			(In Millions)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-27.3%	9.00	13.00	19.00	31.00	50.00	68.00	58.00	69.00	81.00	94.00	110	120	125	78.00	94.00	109	122	71.00	82.00
Current Assets	-27.3%	9.00	13.00	18.00	27.00	46.00	64.00	57.00	68.00	80.00	94.00	109	120	124	77.00	94.00	108	121	68.00	80.00
Cash Equivalents	-29.0%	9.00	13.00	17.00	25.00	34.00	45.00	24.00	26.00	34.00	43.00	72.00	114	121	76.00	92.00	105	118	67.00	79.00
Net PPE	-40.0%	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00
Liabilities	-4.1%	12.00	12.00	15.00	38.00	41.00	38.00	36.00	33.00	33.00	33.00	34.00	31.00	32.00	31.00	34.00	35.00	32.00	33.00	34.00
Current Liabilities	-3.0%	12.00	12.00	14.00	22.00	17.00	13.00	10.00	8.00	12.00	10.00	8.00	5.00	11.00	7.00	8.00	9.00	7.00	6.00	7.00
Long Term Debt	-	-	-	-	15.00	22.00	23.00	25.00	25.00	20.00	21.00	25.00	25.00	20.00	23.00	25.00	25.00	25.00	25.00	25.00
LT Debt, Current	-	-	-	-	6.00	3.00	2.00	-	-	6.00	4.00	-	-	5.00	2.00	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	15.00	22.00	23.00	25.00	25.00	20.00	21.00	25.00	-	-	-	-	-	-	-	-
Shareholder's Equity	-100.0%	-	1.00	4.00	-	9.00	30.00	22.00	36.00	48.00	62.00	75.00	89.00	93.00	47.00	60.00	74.00	90.00	-	-
Retained Earnings	-0.8%	-425	-422	-418	-395	-377	-356	-337	-319	-303	-287	-272	-257	-244	-231	-216	-200	-183	-168	-157
Additional Paid-In Capital	0.1%	423	423	423	388	387	386	359	355	352	349	348	346	338	278	276	275	273	8.00	7.00
Shares Outstanding	0.0%	3.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	-	-	-	-	-	-
Float	-	-	-	-	-	68.00	-	-	-	101	-	-	-	107	-	-	-	107	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Cashflow From Operations	-72.5%	-8,800	-5,100	-15,550	-10,104	-35,500	-16,862	-13,637	-12,217	-14,222	-14,145	-10,063	-10,659	-12,518	-16,531	-13,381	-12,134	-13,250	-12,197	-7,570	-7,476	-7,541
Share Based Compensation	-20.6%	428	539	530	950	594	1,509	1,471	1,667	1,677	1,428	1,360	1,372	1,956	1,599	1,502	1,678	1,507	1,137	881	819	710
Cashflow From Investing	-100.0%	-	525	-19.00	10,170	7,612	13,160	8,230	4,771	4,438	-14,392	-32,864	-3,196	-59.00	-	-34.00	-36.00	-	-47.00	-173	-	-125
Cashflow From Financing	100.0%	-	-27.00	7,279	-301	-58.00	25,318	2,890	-403	675	-4.00	454	6,592	58,381	-	113	-385	64,391	-453	63,764	27.00	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AXLA Income Statement

2023-06-30

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Operating expenses:
Research and development	$ 1,224	$ 16,866	$ 2,657	$ 30,410
General and administrative	2,319	3,753	5,069	8,539
Total operating expenses	3,543	20,619	7,726	38,949
Loss from operations	(3,543)	(20,619)	(7,726)	(38,949)
Other (expense) income:
Interest income	132	65	272	87
Interest expense	0	(752)	0	(1,456)
Other income (expense), net	(2)	0	65	(27)
Total other income (expense), net	130	(687)	337	(1,396)
Net loss	$ (3,413)	$ (21,306)	$ (7,389)	$ (40,345)
Net loss per share, basic (USD per share)	$ (0.05)	$ (0.40)	$ (0.10)	$ (0.86)
Net loss per share, diluted (USD per share)	$ (0.05)	$ (0.40)	$ (0.10)	$ (0.86)
Weighted average common shares outstanding, basic (in shares)	73,688,558	52,616,279	73,678,881	47,052,105
Weighted average common shares outstanding, diluted (in shares)	73,688,558	52,616,279	73,678,881	47,052,105
Comprehensive loss:
Net loss	$ (3,413)	$ (21,306)	$ (7,389)	$ (40,345)
Other comprehensive income (loss):
Unrealized losses on marketable securities	0	4	0	(14)
Comprehensive loss	$ (3,413)	$ (21,302)	$ (7,389)	$ (40,359)

AXLA Balance Sheet

2023-06-30

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 8,884	$ 17,147
Prepaid expenses and other current assets	383	876
Total current assets	9,267	18,023
Property and equipment, net	15	693
Other assets	0	211
Total assets	9,282	18,927
Current liabilities:
Accounts payable	8,395	4,707
Accrued expenses and other current liabilities	1,754	7,849
Current portion of operating lease liability	1,391	1,592
Total current liabilities	11,540	14,148
Operating lease liability	0	569
Other non-current liabilities	0	46
Total liabilities	11,540	14,763
Commitments and contingencies (Note 8)	0	0
Stockholders' equity (deficit):
Common stock, $0.001 par value; 150,000,000 shares authorized, 74,111,726 and 74,074,201 shares issued and 73,692,745 and 73,655,220 shares outstanding at June 30, 2023 and December 31, 2022, respectively	74	74
Additional paid-in capital	423,484	422,517
Treasury stock, 418,981 shares at cost	0	0
Accumulated deficit	(425,816)	(418,427)
Total stockholders' equity (deficit)	(2,258)	4,164
Total liabilities and stockholders' equity (deficit)	$ 9,282	$ 18,927

About Axcella Health Inc

Axcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.

CEO	Mr. William R. Hinshaw Jr.
WEBSITE	axcellahealth.com
INDUSTRY	Biotechnology
EMPLOYEES	11

Axcella Health Inc Frequently Asked Questions

What is the ticker symbol for Axcella Health Inc? What does AXLA stand for in stocks?

AXLA is the stock ticker symbol of Axcella Health Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Axcella Health Inc (AXLA)?

As of Fri Dec 29 2023, market cap of Axcella Health Inc is 1.18 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AXLA stock?

You can check AXLA's fair value in chart for subscribers.

What is the fair value of AXLA stock?

You can check AXLA's fair value in chart for subscribers. The fair value of Axcella Health Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Axcella Health Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AXLA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Axcella Health Inc a good stock to buy?

The fair value guage provides a quick view whether AXLA is over valued or under valued. Whether Axcella Health Inc is cheap or expensive depends on the assumptions which impact Axcella Health Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AXLA.

What is Axcella Health Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 29 2023, AXLA's PE ratio (Price to Earnings) is -0.02 and Price to Sales (PS) ratio is 2.34. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AXLA PE ratio will change depending on the future growth rate expectations of investors.